导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.54% | 4027/4773 |
| 近一周 | -3.38% | 4131/5462 |
| 近一月 | -3.44% | 1762/5421 |
| 近一季 | -2.12% | 1183/5209 |
| 近半年 | -5.70% | 2932/4920 |
| 近一年 | -16.92% | 3828/4366 |
| 近两年 | 30.32% | 2258/2954 |
| 近三年 | 9.79% | 1749/2253 |
| 成立以来 | 11.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.19% 4700/4961 |
9.19% 2496/5312 |
- - |
- - |
| 2025 | 3.69% 3100/4813 |
-7.15% 3426/3635 |
4.47% 752/4076 |
11.43% 3165/4524 |
-4.06% 3384/4813 |
| 2024 | 29.59% 125/3463 |
-5.01% 1825/2808 |
-8.63% 2257/3014 |
42.97% 31/3129 |
4.44% 707/3463 |
| 2023 | 3.94% 252/2656 |
4.18% 1024/2280 |
-2.94% 718/2385 |
7.67% 28/2515 |
-4.53% 1078/2655 |
| 2022 | -26.13% 1372/2207 |
-18.67% 1373/1919 |
1.98% 1391/2016 |
-16.16% 1407/2113 |
6.23% 378/2208 |
| 2021 | -3.84% 932/1822 |
-15.20% 1190/1255 |
6.99% 710/1330 |
4.29% 370/1466 |
1.63% 855/1822 |
| 2020 | 17.44% 763/1250 |
-11.08% 817/1028 |
9.46% 792/1067 |
19.34% 72/1164 |
1.11% 1042/1184 |
| 2019 | 45.23% 153/1092 |
48.60% 9/754 |
-7.10% 544/804 |
-4.98% 784/850 |
10.73% 103/918 |
| 2018 | -24.86% 335/834 |
- - |
- - |
- - |
-1.67% 19/691 |
| 2017 | -7.43% 521/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证全指证券公司ETF VS. 长安沪深300非周期A(740101) |